SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies
Japan launches its first nationwide multi-omics study of blood cancers, positioning doctors to match treatments to each patient's unique tumor biology.
The SCRUM-Japan MONSTAR3 hematology cohort is a prospective nationwide platform enrolling 400 patients with hematologic malignancies for integrated multi-omics profiling (WES, WTS, spatial transcriptomics, proteomics, metabolomics, microbiome, and NGS-based MRD). This is the first nationwide multi-omics initiative of this scope for hematologic cancers in Japan, with initial operational feasibility confirmed, positioning it as a major future source of precision hematology data.
What the study was
- Study design
- Prospective multi-omics cohort (platform paper)
- Population
- 400 patients with newly diagnosed or relapsed/refractory hematologic malignancies (Japan nationwide, enrollment started Dec 2024)
- Sample size
- 400
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- International Journal of Clinical Oncology
Why it surfaced
Platform/feasibility paper with no primary outcomes yet. Strong infrastructure relevance: nationwide Japan, MRD + multi-omics + spatial transcriptomics in lymphoma/leukemia/plasma cell neoplasms is highly relevant to future precision hematology. Scored 7 (top STANDARD) given its strategic significance despite being early-stage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.